Drugs / Avotermin
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01029158 | Aug 2009 → Sep 2010 | — | Renovo | Completed | No outcome recorded |
| Phase 1 | NCT00978302 | May → Aug 2001 | — | Renovo | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT00710333 | Jul 2008 → Oct 2009 | keloid | Renovo | Completed | No outcome recorded |
| Phase 1/2 | NCT00984581 | Apr 2003 → Aug 2004 | — | Renovo | Completed | No outcome recorded |
| Phase 1/2 | NCT00977951 | Sep 2002 → Sep 2003 | — | Renovo | Completed | No outcome recorded |
| Phase 1/2 | NCT00847795 | Sep 2002 → Jun 2003 | — | Renovo | Completed | No outcome recorded |
| Phase 1/2 | NCT00978367 | Feb → Nov 2002 | — | Renovo | Completed | No outcome recorded |
| Phase 1/2 | NCT00847925 | Nov 2001 → Sep 2003 | — | Renovo | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT00430326 | Nov 2006 → Jan 2009 | varicose disease | Renovo | Completed | No outcome recorded |
| Phase 2 | NCT00432328 | Oct 2006 → ? | — | Renovo | Terminated | No outcome recorded |
| Phase 2 | NCT00629811 | Sep 2006 → Aug 2007 | — | Renovo | Completed | No outcome recorded |
| Phase 2 | NCT00627536 | Jul 2006 → Mar 2007 | — | Renovo | Completed | No outcome recorded |
| Phase 2 | NCT00436449 | Dec 2004 → Oct 2007 | — | Renovo | Completed | No outcome recorded |
| Phase 2 | NCT00656227 | Apr 2004 → Jul 2007 | non-neoplastic nevus | Renovo | Unknown | No outcome recorded |
| Phase 2 | NCT00984503 | Oct 2003 → Jan 2006 | — | Renovo | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00742443 | Dec 2008 → Jan 2011 | — | Renovo | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07137130 | Feb → May 2026 overdue | hyperpigmentation of the skin | Indonesia University | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00836147 Comparator | Feb 2009 → Jun 2010 | keloid | Renovo | Completed | No outcome recorded |
| Phase 1/2 | NCT00469235 Comparator | Jun 2007 → Mar 2009 | keloid | Renovo | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00432211 Comparator | May 2006 → Jul 2008 | — | Renovo | Unknown | No outcome recorded |
| Phase 2 | NCT00594581 Comparator | Oct 2003 → Mar 2005 | — | Renovo | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00821457 Comparator | Jan 2009 → Mar 2010 | — | Renovo | Withdrawn | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avotermin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00847925 ↗ |
| Known as | Avotermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108833 ↗ |
| Known as | Avotermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108833 ↗ |
| Known as | Human tgfb3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108833 ↗ |
| Known as | Juvista | “Juvista (Avotermin) in Breast Reduction Surgery Scars” NCT00432328 ↗ |
| Known as | RN1001 | “A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision” NCT00656227 ↗2“RN1001 (Avotermin) in Scar Improvement Following Breast Augmentation” NCT00436449 ↗ “Avotermin (RN1001)” NCT00847925 ↗ |
| Known as | TGF Beta 3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07137130 ↗ |
| Known as | TGF-β3 | “Moon et al. examined the effects of TGF-β3 on melanogenesis in human melanocytes co-cultured with skin cells irradiated with ultraviolet (UV) light, and in UV-irradiated human skin.” NCT07137130 ↗1“This study was performed to assess the efficacy of intradermal avotermin (TGF-β3) for the improvement of scar appearance following scar revision surgery.” PMID 21701333 ↗ Jul 2011 |
| Action | Inhibit | “TGF-β3 inhibits melanogenesis by inhibiting MITF expression” NCT07137130 ↗ |
| Modality | Protein / enzyme biologic | “transforming growth factor β3 (avotermin) improved scar appearance” PMID 21618480 ↗ Mar 2011 |
| Route | Other | “administered by intradermal injection to the groin and distal wound margins of one leg” PMID 21618480 ↗ Mar 2011 |
| Target | MITF | “TGF-β3 inhibits melanogenesis by inhibiting MITF expression” NCT07137130 ↗ |